These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

656 related items for PubMed ID: 16199246

  • 1. An open-label, noncomparative study of miglustat in type I Gaucher disease: efficacy and tolerability over 24 months of treatment.
    Pastores GM, Barnett NL, Kolodny EH.
    Clin Ther; 2005 Aug; 27(8):1215-27. PubMed ID: 16199246
    [Abstract] [Full Text] [Related]

  • 2. Effect of miglustat on bone disease in adults with type 1 Gaucher disease: a pooled analysis of three multinational, open-label studies.
    Pastores GM, Elstein D, Hrebícek M, Zimran A.
    Clin Ther; 2007 Aug; 29(8):1645-54. PubMed ID: 17919546
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Short-term effect of miglustat in every day clinical use in treatment-naïve or previously treated patients with type 1 Gaucher's disease.
    Giraldo P, Latre P, Alfonso P, Acedo A, Alonso D, Barez A, Corrales A, Franco R, Roldan V, Serrano S, Pocovi M.
    Haematologica; 2006 May; 91(5):703-6. PubMed ID: 16627252
    [Abstract] [Full Text] [Related]

  • 6. Miglustat (Zavesca) in type 1 Gaucher disease: 5-year results of a post-authorisation safety surveillance programme.
    Hollak CE, Hughes D, van Schaik IN, Schwierin B, Bembi B.
    Pharmacoepidemiol Drug Saf; 2009 Sep; 18(9):770-7. PubMed ID: 19507165
    [Abstract] [Full Text] [Related]

  • 7. Sustained therapeutic effects of oral miglustat (Zavesca, N-butyldeoxynojirimycin, OGT 918) in type I Gaucher disease.
    Elstein D, Hollak C, Aerts JM, van Weely S, Maas M, Cox TM, Lachmann RH, Hrebicek M, Platt FM, Butters TD, Dwek RA, Zimran A.
    J Inherit Metab Dis; 2004 Sep; 27(6):757-66. PubMed ID: 15505381
    [Abstract] [Full Text] [Related]

  • 8. Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis.
    Cox T, Lachmann R, Hollak C, Aerts J, van Weely S, Hrebícek M, Platt F, Butters T, Dwek R, Moyses C, Gow I, Elstein D, Zimran A.
    Lancet; 2000 Apr 29; 355(9214):1481-5. PubMed ID: 10801168
    [Abstract] [Full Text] [Related]

  • 9. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues.
    Cady R, Schreiber C.
    Headache; 2008 Jun 29; 48(6):900-13. PubMed ID: 18047501
    [Abstract] [Full Text] [Related]

  • 10. Successful switch from enzyme replacement therapy to miglustat in an adult patient with type 1 Gaucher disease: a case report.
    Giuffrida G, Lombardo R, Di Francesco E, Parrinello L, Di Raimondo F, Fiumara A.
    J Med Case Rep; 2016 Nov 08; 10(1):315. PubMed ID: 27821156
    [Abstract] [Full Text] [Related]

  • 11. Miglustat: new drug. In type 1 Gaucher's disease : a slight benefit after imiglucerase therapy.
    Prescrire Int; 2005 Oct 08; 14(79):168-70. PubMed ID: 16285070
    [Abstract] [Full Text] [Related]

  • 12. Effective treatment of an elderly patient with Gaucher's disease and Parkinsonism: a case report of 24 months' oral substrate reduction therapy with miglustat.
    Hughes DA, Ginsberg L, Baker R, Goodwin S, Milligan A, Richfield L, Mehta AB.
    Parkinsonism Relat Disord; 2007 Aug 08; 13(6):365-8. PubMed ID: 17049454
    [Abstract] [Full Text] [Related]

  • 13. Miglustat therapy in type 1 Gaucher disease: clinical and safety outcomes in a multicenter retrospective cohort study.
    Kuter DJ, Mehta A, Hollak CE, Giraldo P, Hughes D, Belmatoug N, Brand M, Muller A, Schaaf B, Giorgino R, Zimran A.
    Blood Cells Mol Dis; 2013 Aug 08; 51(2):116-24. PubMed ID: 23683771
    [Abstract] [Full Text] [Related]

  • 14. Evaluation of miglustat as maintenance therapy after enzyme therapy in adults with stable type 1 Gaucher disease: a prospective, open-label non-inferiority study.
    Cox TM, Amato D, Hollak CE, Luzy C, Silkey M, Giorgino R, Steiner RD, Miglustat Maintenance Study Group.
    Orphanet J Rare Dis; 2012 Dec 27; 7():102. PubMed ID: 23270487
    [Abstract] [Full Text] [Related]

  • 15. Comparative efficacy of dose regimens in enzyme replacement therapy of type I Gaucher disease.
    Altarescu G, Schiffmann R, Parker CC, Moore DF, Kreps C, Brady RO, Barton NW.
    Blood Cells Mol Dis; 2000 Aug 27; 26(4):285-90. PubMed ID: 11042029
    [Abstract] [Full Text] [Related]

  • 16. Multicenter, randomized, double-blind, active-controlled, parallel-group trial of the long-term (6-12 months) safety of acetaminophen in adult patients with osteoarthritis.
    Temple AR, Benson GD, Zinsenheim JR, Schweinle JE.
    Clin Ther; 2006 Feb 27; 28(2):222-35. PubMed ID: 16678643
    [Abstract] [Full Text] [Related]

  • 17. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.
    Hurwitz BJ, Jeffery D, Arnason B, Bigley K, Coyle P, Goodin D, Kaba S, Kirzinger S, Lynch S, Mandler R, Mikol D, Rammohan K, Sater R, Sriram S, Thrower B, Boateng F, Jakobs P, Wash MB, Bogumil T.
    Clin Ther; 2008 Jun 27; 30(6):1102-12. PubMed ID: 18640466
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease.
    Besarab A, Salifu MO, Lunde NM, Bansal V, Fishbane S, Dougherty FC, Beyer U, Ba16285 Study Investigators.
    Clin Ther; 2007 Apr 27; 29(4):626-39. PubMed ID: 17617286
    [Abstract] [Full Text] [Related]

  • 20. Spontaneous regression of disease manifestations can occur in type 1 Gaucher disease; results of a retrospective cohort study.
    Boomsma JM, van Dussen L, Wiersma MG, Groener JE, Aerts JM, Maas M, Hollak CE.
    Blood Cells Mol Dis; 2010 Mar 15; 44(3):181-7. PubMed ID: 20074983
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.